These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32394628)

  • 1. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.
    Zhu MR; Du DH; Hu JC; Li LC; Liu JQ; Ding H; Kong XQ; Jiang HL; Chen KX; Luo C
    Acta Pharmacol Sin; 2018 Feb; 39(2):302-310. PubMed ID: 28858300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
    Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
    Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
    Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
    Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
    Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
    J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Identification of Novel Allosteric PRC2 Inhibitors.
    Read JA; Tart J; Rawlins PB; Gregson C; Jones K; Gao N; Zhu X; Tomlinson R; Code E; Cheung T; Chen H; Kawatkar SP; Bloecher A; Bagal S; O'Donovan DH; Robinson J
    ACS Chem Biol; 2019 Oct; 14(10):2134-2140. PubMed ID: 31525019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
    Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
    Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
    Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
    Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay.
    Murashima A; Shinjo K; Katsushima K; Onuki T; Kondoh Y; Osada H; Kagaya N; Shin-Ya K; Kimura H; Yoshida M; Murakami S; Kondo Y
    J Biochem; 2019 Jul; 166(1):41-50. PubMed ID: 30690451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
    Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
    Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
    Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
    J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase.
    Simard JR; Plant M; Emkey R; Yu V
    Assay Drug Dev Technol; 2013 Apr; 11(3):152-62. PubMed ID: 23409774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
    Martin MC; Zeng G; Yu J; Schiltz GE
    J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.